Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.
- Phase 2 CYP-001 and Phase 3 CYP-004 trials failed to demonstrate efficacy
- $9.25 million annual loss and $553,774 net liability position
- $1.35 million impairment recognised against licensed intellectual property
- All employee positions made redundant after year end
- $600,000 secured R&D tax incentive loan extends forecast runway beyond FY2027
Twin Trial Failures Force Cynata Into Strategic Reset
Cynata Therapeutics (ASX:CYP) has arrived at the most consequential point in its history with both of its flagship efficacy trials failing to support their intended outcomes. The Phase 2 CYP-001 trial in acute graft-versus-host disease was terminated after showing no meaningful benefit over steroids alone, while the Phase 3 SCUlpTOR trial of CYP-004 in knee osteoarthritis missed both co-primary endpoints. Neither study raised new safety concerns, but the efficacy setbacks have fundamentally changed the company’s immediate prospects.
The osteoarthritis trial produced a substantial and durable reduction in knee pain from baseline, but the response was also seen in the placebo group and there was no statistically significant difference between CYP-004 and placebo at any measured timepoint. In the aGvHD study, involving 65 patients across Australia, the United States and Europe, the active and control groups likewise showed no significant difference in the primary or key secondary endpoints.
Cash Position Improves After Emergency Cost Cuts
The financial statements show a business under severe pressure. Cynata recorded a $9.25 million loss for the year ended 30 June 2026, compared with $9.39 million a year earlier, while operating cash outflows reached $6.74 million. Cash at year end was just $897,418, down from $5.05 million, and net assets swung from $5.98 million to a net liability position of $553,774.
After year end, every employee position was made redundant, including those of chief executive and managing director Kilian Kelly, chief medical officer Jolanta Airey and chief business officer Mathias Kroll. Kelly remains on the board as an unpaid non-executive director, Darryl Maher has resigned as a director, and the remaining board members have waived their fees from 1 July 2026. The company has also terminated or suspended outsourced activities as far as possible while preserving its intellectual property.
A $600,000 R&D tax incentive loan lifted pro forma cash to about $1.5 million in early July. The facility is secured against company assets and the expected FY2026 R&D rebate of approximately $1.7 million; once that rebate arrives and the loan is repaid, Cynata expects to receive a further roughly $1 million. Management forecasts a cash runway beyond the end of FY2027, although the report makes clear that this depends on disciplined spending and access to future funding or strategic capital.
Cymerus Value Written Down As Board Reviews Options
Cynata recognised a $1.35 million impairment against licensed intellectual property, reducing its intangible assets to $234,965. The company attributed the write-down to the failed aGvHD and osteoarthritis results and said the affected patents were licensed from the Wisconsin Alumni Research Foundation. Intellectual property acquired from TekCyte for the CYP-006TK wound-dressing product was not affected by those results.
The remaining clinical thread is the investigator-led Phase 1/2 NEREID kidney transplantation trial at Leiden University Medical Center. Its first cohort comprised three patients, with no transplant rejection episodes or safety concerns reported, and an independent data and safety monitoring board recommended proceeding to a second cohort. That cohort, involving three more patients and two infusions per patient, is ongoing; the report does not yet provide an efficacy conclusion.
The board says it is assessing ways to realise value from Cymerus, including licensing, partnering or other strategic transactions, while also considering whether to acquire or in-license new assets. That ambition sits alongside a disclosed material uncertainty over going concern: the directors believe the company can continue, but acknowledge its limited resources, lack of operating revenue, contractual obligations and dependence on additional funding. The next test is therefore not only whether the kidney programme produces a useful signal, but whether anyone is prepared to fund or partner the platform after two high-profile efficacy disappointments.
Bottom Line?
Cynata has bought time, not certainty: the board must convert the remaining kidney trial and Cymerus intellectual property into a credible funded strategy before the forecast runway runs down.
Questions in the middle?
- Can the second NEREID cohort generate evidence strong enough to support further development or partnership discussions?
- Will Cynata secure a licensing, partnering or asset transaction on terms that preserve meaningful value for existing shareholders?
- How quickly will cash commitments, loan repayment and ongoing clinical costs consume the company’s post-restructuring runway?